MARSEILLE, France–(BUSINESS WIRE)–Regulatory Information:
Innate Pharma SA (OTC:) (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Firm) as we speak introduced that members of its govt workforce are scheduled to take part within the upcoming investor convention, detailed beneath.
Van Lanschot Kempen convention
Occasion Date: April 16-17, 2024 | Amsterdam, Netherlands
About Innate Pharma
Innate Pharma S.A. is a world, clinical-stage biotechnology firm growing immunotherapies for most cancers sufferers. Its revolutionary strategy goals to harness the innate immune system by therapeutic antibodies and its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio consists of lead proprietary program lacutamab, developed in superior type of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca (NASDAQ:) in non-small cell lung most cancers, in addition to ANKET ® multi-specific NK cell engagers to handle a number of tumor sorts.
Innate Pharma is a trusted companion to biopharmaceutical firms akin to Sanofi (NASDAQ:) and AstraZeneca, in addition to main analysis establishments, to speed up innovation, analysis and improvement for the good thing about sufferers.
Headquartered in Marseille, France with a US workplace in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq within the US.
Be taught extra about Innate Pharma at www.innate-pharma.com and observe us on LinkedIn and X.
Details about Innate Pharma shares
ISIN code |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking info and threat elements
This press launch accommodates sure forward-looking statements, together with these throughout the which means of the Personal Securities Litigation Reform Act of 1995. Using sure phrases, together with consider, potential, count on and can and comparable expressions, is meant to determine forward-looking statements. Though the corporate believes its expectations are primarily based on affordable assumptions, these forward-looking statements are topic to quite a few dangers and uncertainties, which might trigger precise outcomes to vary materially from these anticipated. These dangers and uncertainties embody, amongst different issues, the uncertainties inherent in analysis and improvement, together with associated to security, development of and outcomes from its ongoing and deliberate scientific trials and preclinical research, evaluation and approvals by regulatory authorities of its product candidates, the Firm’s commercialization efforts and the Firm’s continued means to lift capital to fund its improvement. For a further dialogue of dangers and uncertainties which might trigger the corporate’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please consult with the Threat Components (Facteurs de Risque”) part of the Common Registration Doc filed with the French Monetary Markets Authority (AMF), which is offered on the AMF web site http://www.amf-france.org or on Innate Pharma’s web site, and public filings and experiences filed with the U.S. Securities and Alternate Fee (SEC), together with the Firm’s Annual Report on Kind 20-F for the 12 months ended December 31, 2023, and subsequent filings and experiences filed with the AMF or SEC, or in any other case made public, by the Firm.
This press launch and the knowledge contained herein don’t represent a suggestion to promote or a solicitation of a suggestion to purchase or subscribe to shares in Innate Pharma in any nation.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20240408367312/en/
Traders
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
[email protected]
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
[email protected]
Supply: Innate Pharma SA